[(4-氯苯基)甲基]丙二酸 | 21405-64-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: [(4-氯苯基)甲基]丙二酸
• 英文名称: <(4-chlorophenyl)methyl>propanedioic acid
• 英文别名: 2-(4-chlorobenzyl)malonic acid；4-chlorobenzylmalonic acid；(4-chloro-benzyl)-malonic acid；(4-Chlor-benzyl)-malonsaeure；p-Chlorobenzylmalonic Acid；p-Chlorbenzylmalonsaeure；2-[(4-chlorophenyl)methyl]propanedioic acid
• CAS: 21405-64-1
• 化学式: C₁₀H₉ClO₄
• 分子量: 228.632
• InChiKey: QNZGBKFZLKIUPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [(4-氯苯基)甲基]丙二酸 在 palladium diacetate 作用下， 以 xylene 为溶剂， 生成 vinyl 3-(4-chlorophenyl)propanoate
  参考文献：
  名称：

  The effect of vinyl esters on the enantioselectivity of the lipase-catalysed transesterification of alcohols

  摘要：

  The enantioselectivity of the lipase from Pseudomonas cepacia (PCL) in the transesterification of 2-phenyl-1-propanol I was studied using a series of vinyl 3-arylpropanoates as acyl donors. The most enantioselective transesterification reaction of the alcohol was attained by using vinyl 3-(p-iodophenyl)- or 3-(p-trifluoromethylphenyl)propanoates, with enantiomer ratios, E, of 116 and 138, respectively. Vinyl 3-phenylpropanoate was also effective for the resolution of 1 mediated by lipases from P. fluorescens and porcine pancreas and for the PCL-catalysed transesterification of several 2-phenyl-1-alkanols. The enantiomeric resolution of 1 was practically carried out by the first enantioselective transesterification using PCL and vinyl 3-(p-iodophenyl)propanoate to afford (R)-1 and then the enantioselective hydrolysis of the resultant ester to afford (S)-1. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00083-0
• 作为产物：
  描述：

  2-[(4-氯苯基)甲基]丙二酸二乙酯 在 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 [(4-氯苯基)甲基]丙二酸
  参考文献：
  名称：

  含新烟碱部分的中离子吡啶并[1,2-α]嘧啶酮衍生物的合成及杀虫活性。

  摘要：

  设计，合成并评价了含有新烟碱部分的中离子吡啶并[1,2-α]嘧啶酮衍生物。一些标题化合物显示出对蚜虫的显着杀虫特性。化合物I13表现出令人满意的对Craccivora的杀虫活性。同时，对化合物I13处理的无标记蛋白质组学分析共鉴定出821种蛋白质。其中35种蛋白质被上调，而108种蛋白质被下调。这些蛋白质的差异表达反映了细胞结构和代谢的变化。

  DOI：

  10.3390/molecules23051217

文献信息

• Triazolopyrimidines
  申请人：——

  公开号：US20040063729A1

  公开（公告）日：2004-04-01

  The invention relates to novel triazolopyrimidines of the formula 1 wherein X represents halogen, Y represents a hydrogen atom or halogen, and R has the meanings given in the disclosure, to a process for the preparation of the new compounds, and to their use as microbicides.

  这项发明涉及公式 1 中的新型三唑嘧啶化合物， 其中 X代表卤素， Y代表氢原子或卤素，以及 R具有披露中给出的含义， 以及制备新化合物的方法，以及它们作为微生物杀灭剂的用途。
• Sulfur-containing acylamino acids. II. Syntheses and angiotensin I converting enzyme-inhibitory activites of N-mercaptoalkanoyl-S-ethyl-L-cysteine.
  作者：TAKETOSHI KOMORI、KATSUMI ASANO、YASUTO SASAKI、HIROMI HANAI、SHIRO MORIMOTO、MIKIO HORI

  DOI：10.1248/cpb.35.2388

  日期：——

  N-Mercaptoalkanoyl derivatives of sulfur-containing amino acids were synthesized as candidate angiotensin I converting enzyme (ACE) inhibitors. Among them, N-[3-mercapto-2- (4-methoxybenzyl) propanoyl] -S-ethyl-L-cysteine (5d) was found to be the most potent inhibitor of ACE, with an IC50 value of 0.045μM. The maximum hypotensive effect of this compound was almost equal to that of captopril in anesthetized rats.

  含有硫氨基酸的N-巯基烷酰基衍生物被合成作为候选血管紧张素I转化酶（ACE）抑制剂。其中，N-[3-巯基-2-(4-甲氧基苄基)丙酰基]-S-乙基-L-半胱氨酸（5d）被发现是最强效的ACE抑制剂，其IC50值为0.045μM。该化合物在麻醉大鼠中的最大降压效果几乎与卡托普利相当。
• Mesoionic xanthine analogs: phosphodiesterase inhibitory and hypotensive activity
  作者：Richard A. Glennon、Michael E. Rogers、J. Doyle Smith、M. K. El-Said、John L. Egle

  DOI：10.1021/jm00138a002

  日期：1981.6

  Several mesoionic thiazolo[3,2-alphapyrimidines and mesoionic 1,3,4-thiadiazol[3,2-alpha-pyrimidines were evaluated as inhibitors of cyclic-AMP phosphodiesterase. While small alkyl substituents at the 6 position have no significant effect on activity, phenyl and benzyl substituents enhance activity. Mesoionic structures such as 1 (R2 = H; R8 = Et) possess 20 to 40 times the activity of theophylline

  评价了几种中离子噻唑并[3,2-α-嘧啶和中离子1,3,4-噻二唑[3,2-α-嘧啶]作为环AMP磷酸二酯酶的抑制剂。尽管在6位的小的烷基取代基对活性没有显着影响，但是苯基和苄基取代基增强了活性。当R6取代基为苯基或4-氯苄基时，介电结构如1（R2 = H； R8 = Et）的活性为茶碱的20至40倍。在2位上的甲基和乙基取代基本上消除了活性。尽管受到溶解性问题的困扰，但是发现一些中离子衍生物在体内显示出弱的降压作用。
• METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20140107094A1

  公开（公告）日：2014-04-17

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括以下式的化合物：其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。该发明还包括一种治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还包括通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。
• Methylene linked quinolinyl modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US09290476B2

  公开（公告）日：2016-03-22

  The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及式I的化合物，其中：R1，R2，R3，R4，R5，R6，R7，R8和R9在说明书中有定义。本发明还涉及一种治疗或改善综合征、疾病或疾患的方法，所述综合征、疾病或疾患是类风湿性关节炎或银屑病。本发明还涉及通过给予至少一种权利要求1中的化合物的治疗有效量来调节哺乳动物中的RORγt活性的方法。